RFA-AI-22-028: Partnerships for the Development of Novel Therapeutics to Combat Select Antibiotic Resistant Bacteria and Fungi (R01 Clinical Trial Not Allowed)
Closed
This grant is closed. Who won this program's grants before is below, and similar open grants are at the end of the page. It is in our archive of National Institutes of Health notices from 2022.
National Institutes of Health offered grants of up to $650,000 to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. Applications closed on July 29, 2022.
From the official notice on Grants.gov, last changed April 5, 2022. Checked November 7, 2026.
- Award ceiling$650,000
- Cost sharingNot required
- Funding typeGrant
About this NIH notice
- Activity codeR01
- Clinical trialsNot allowed
- Funded byNIAID
- Median yearly award$977,797
- Typical project length5 years
- R01, Research Project Grant. NIH's standard grant for a defined research project led by a named investigator, usually for up to five years. Other open R01 notices.
Projects funded under RFA-AI-22-028 were run by National Institute of Allergy and Infectious Diseases (NIAID, 6 projects). Contact the program officer at the institute that fits your project before you apply; the notice lists them.
Application due dates, page limits and budget limits are set in the notice. Read RFA-AI-22-028 in the NIH Guide.
Key dates
| Posted | April 5, 2022 |
|---|---|
| Deadline | July 29, 2022 |
| Archived by Grants.gov | September 3, 2022 |
Who can apply
This opportunity was open to nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses.
All 15 applicant types the notice lists
- State governments
- County governments
- City or township governments
- Special district governments
- Independent school districts
- Public and State controlled institutions of higher education
- Native American tribal governments (Federally recognized)
- Public housing authorities/Indian housing authorities
- Native American tribal organizations (other than Federally recognized tribal governments)
- Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education
- Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education
- Private institutions of higher education
- For profit organizations other than small businesses
- Small businesses
- Others (see text field entitled "Additional Information on Eligibility" for clarification)
Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
Is this a realistic fit?
- Projects NIH funded under this notice had a median yearly award of $977,797; it allows up to $650,000 per award.
- Most of the program's money (67% over five years) went to colleges and universities.
- No cost sharing or match is required.
What the grant funds
The purpose of this Funding Opportunity Announcement (FOA) is to solicit research applications for milestone-driven projects focused on preclinical development of lead candidate therapeutics and related countermeasures against antibiotic resistant Acinetobacter baumannii, Pseudomonas aeruginosa, Enterobacteriaceae, or Candida auris. Applications must include a Product Development Strategy attachment. Substantive investment by industrial participants is highly encouraged.
Funded under RFA-AI-22-028 so far
NIH funded 6 projects under RFA-AI-22-028 in fiscal 2023 to 2026, at 6 institutions. The median yearly award was $977,797.
| Project | Institution | Fiscal year | Award |
|---|---|---|---|
| Developing a novel class of peptide antibiotics targeting carbapenem-resistant Gram-negative organisms | Florida International University | 2026 | $870,109 |
| Monoclonal Antibody to Combat Pseudomonas Aeruginosa | Emory University | 2026 | $659,598 |
| Optimization, Manufacturing and Testing of a Lead Therapeutic Bacteriophage Cocktail for the Treatment of Antibiotic-Resistant Klebsiella pneumoniae Infections | J. Craig Venter Institute, Inc. | 2026 | $1.8 million |
| Host Directed Orynotide for MDR Gram Negative Bacterial Infections | University of Southern California | 2026 | $1.0 million |
| FabI Inhibitors as Potent, Gut Microbiome-Sparing Antibiotics | University of Illinois at Urbana-Champaign | 2026 | $977,797 |
| Biomimetic Macrophage Membrane-Coated Nanosponges: A Novel Therapeutic for Multidrug-Resistant Pseudomonas aeruginosa and Acinetobacter baumannii Hospital-Associated Pneumonia | University of California, San Diego | 2026 | $972,869 |
Who has won Allergy and Infectious Diseases Research grants before
From fiscal 2021 to 2025, Allergy and Infectious Diseases Research (93.855) awarded $22 billion across 13,282 grant awards, an average of $1.6 million per award.
| Recipient | State | Awards | Amount |
|---|---|---|---|
| Fred Hutchinson Cancer Center | Washington | 85 | $938 million |
| Duke University | North Carolina | 230 | $781 million |
| University of California, Los Angeles | California | 138 | $745 million |
| The Johns Hopkins University | Maryland | 321 | $668 million |
| Emory University | Georgia | 282 | $650 million |
Applying now
This notice no longer takes applications. Agencies often post the same opportunity again under a new number, so check the program's notices on Grants.gov and the similar open grants below.
The notice on Grants.gov keeps its full text and attachments, which is useful for planning a resubmission.
Questions people ask
Is RFA-AI-22-028 still open?
No. It closed on July 29, 2022.
Who can apply for Partnerships for the Development of Novel Therapeutics to Combat Select Antibiotic Resistant Bacteria and Fungi (R01 Clinical Trial Not Allowed)?
National Institutes of Health accepted applications from nonprofits, colleges and universities, state and local governments, tribes, small businesses and businesses. The notice adds further conditions, so read its eligibility section.
What is the deadline for Partnerships for the Development of Novel Therapeutics to Combat Select Antibiotic Resistant Bacteria and Fungi (R01 Clinical Trial Not Allowed)?
Closed July 29, 2022. Applications are no longer accepted; the program's newer notices are on this page when there are any.
How much funding is available?
Awards of up to $650,000 each.
Who has been funded under RFA-AI-22-028?
NIH RePORTER lists 6 projects funded under RFA-AI-22-028 in fiscal 2023 to 2026, at 6 institutions. The most were at Florida International University, Emory University, J. Craig Venter Institute, Inc.
Who has won Allergy and Infectious Diseases Research grants before?
The largest recipients over five fiscal years were Fred Hutchinson Cancer Center, Duke University, University of California, Los Angeles. The program made 13,282 awards worth $22 billion in that time.
Similar open grants
- NCCIH Natural Product Mid Phase Clinical Trial (R01 Clinical Trial Required)
- NCCIH Multi-Site Feasibility Clinical Trials of Mind and Body Interventions (R01 Clinical Trial Required)
- Investigator Initiated Clinical Trials of Complementary and Integrative Interventions Delivered Remotely or via mHealth (R01 Clinical Trial Required)
- Ethical, Legal and Social Implications (ELSI) Research (R01 Clinical Trial Optional)
- Competing Revisions to Existing NIH Single Project Research Grants and Cooperative Agreements (Clinical Trial Optional)
- Interventions to expand cancer screening and preventive services to ADVANCE health in populations that experience health disparities (R01, Clinical Trial Required)